Literature DB >> 18580308

Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification.

Mark E Sherman1, Brigitte M Ronnett, Olga B Ioffe, Douglas A Richesson, Brenda B Rush, Andrew G Glass, Nilanjan Chatterjee, Maire A Duggan, James V Lacey.   

Abstract

BACKGROUND: Identifying which categories in the World Health Organization classification of endometrial hyperplasia contribute to suboptimal reproducibility is clinically important.
METHODS: A 2-member panel reviewed 209 endometrial biopsy/curettage specimens originally diagnosed as incident endometrial hyperplasia as part of a progression study. Original diagnoses included the following: disordered proliferative endometrium, simple hyperplasia, complex hyperplasia, and atypical hyperplasia; panel diagnoses also included negative and carcinoma. We assessed percentage agreement and kappa statistics+/-standard errors (K+/-SE).
RESULTS: Original and panel diagnoses (combining negative with disordered proliferative endometrium; atypical hyperplasia with carcinoma) agreed for 34.9% of biopsies (K-unweighted+/-SE=0.18+/-0.03; K-weighted+/-SE=0.27+/-0.04). Panelists' diagnoses agreed (using 6 categories) for 51.7% of biopsies, corresponding to K-unweighted+/-SE=0.37+/-0.03, improving with weighting to K-weighted+/-SE=0.63+/-0.05. Reproducibility based on a 2-tier classification ([negative, disordered proliferative endometrium, simple hyperplasia, or complex hyperplasia] versus [atypical hyperplasia or carcinoma]) increased agreement between original and panel diagnoses to 82.8%, K-unweighted+/-SE=0.37+/-0.06, and between panelists to 87.0%, K-unweighted+/-SE=0.63+/-0.07. Agreement between panelists at a cutpoint of complex hyperplasia and more severe versus simple hyperplasia or less severe was 88.0%, K-unweighted+/-SE=0.72+/-0.07.
CONCLUSIONS: Developing and prospectively testing a binary system of classifying endometrial hyperplasia on endometrial biopsy may aid efforts to improve interobserver reproducibility.

Entities:  

Mesh:

Year:  2008        PMID: 18580308     DOI: 10.1097/PGP.0b013e3181659167

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  8 in total

1.  Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies.

Authors:  James V Lacey; George L Mutter; Marisa R Nucci; Brigitte M Ronnett; Olga B Ioffe; Brenda B Rush; Andrew G Glass; Douglas A Richesson; Nilanjan Chatterjee; Bryan Langholz; Mark E Sherman
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

Review 2.  [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology].

Authors:  S Lax
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

3.  Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development.

Authors:  Omar Habeeb; Lee Goodglick; Robert A Soslow; Rajiv G Rao; Lynn K Gordon; Osvaldo Schirripa; Steve Horvath; Jonathan Braun; David B Seligson; Madhuri Wadehra
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

4.  Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development.

Authors:  Peggy S Sullivan; Erin L Maresh; David B Seligson; Omar Habeeb; Madhuri Wadehra; Lee Goodglick; Oliver Dorigo
Journal:  Mod Pathol       Date:  2012-03-30       Impact factor: 7.842

Review 5.  Precursors of endometrial and ovarian carcinoma.

Authors:  Robert J Kurman; Thomas G McConnell
Journal:  Virchows Arch       Date:  2009-10-27       Impact factor: 4.064

6.  Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

Authors:  James V Lacey; Mark E Sherman; Brenda B Rush; Brigitte M Ronnett; Olga B Ioffe; Máire A Duggan; Andrew G Glass; Douglas A Richesson; Nilanjan Chatterjee; Bryan Langholz
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

7.  Discovery and validation of methylation markers for endometrial cancer.

Authors:  Nicolas Wentzensen; Jamie N Bakkum-Gamez; J Keith Killian; Joshua Sampson; Richard Guido; Andrew Glass; Lisa Adams; Patricia Luhn; Louise A Brinton; Brenda Rush; Lori d'Ambrosio; Munira Gunja; Hannah P Yang; Montserrat Garcia-Closas; James V Lacey; Jolanta Lissowska; Karl Podratz; Paul Meltzer; Viji Shridhar; Mark E Sherman
Journal:  Int J Cancer       Date:  2014-03-31       Impact factor: 7.396

8.  Interobserver agreement for endometrial cancer characteristics evaluated on biopsy material.

Authors:  S Nofech-Mozes; N Ismiil; V Dubé; R S Saad; Z Ghorab; A Grin; I Ackerman; M A Khalifa
Journal:  Obstet Gynecol Int       Date:  2012-02-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.